Acute heart failure syndromes: Epidemiology, risk stratification and prognostic factors

Acute Cardiac Care

Volumn 11, Issue 2, 2009, Pages 77-82

  Harinstein, Matthew E ^a   Filippatos, Gerasimos S ^b   Gheorghiade, Mihai ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

Author keywords

Acute heart failure; epidemiology; prognosis

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; SODIUM;

ACUTE HEART FAILURE; BLOOD PRESSURE; BODY WEIGHT; CONFERENCE PAPER; CORONARY ARTERY DISEASE; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; KIDNEY FUNCTION; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; QRS COMPLEX; RISK ASSESSMENT; SODIUM BLOOD LEVEL; ACUTE DISEASE; EUROPE; HEART FAILURE; METHODOLOGY; MORBIDITY; REVIEW; RISK FACTOR; SURVIVAL RATE; SYNDROME;

ACUTE DISEASE; EUROPE; HEART FAILURE; HUMANS; MORBIDITY; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; SYNDROME;

EID: 70249129466     PISSN: 17482941     EISSN: 1748295X     Source Type: Journal    
DOI: 10.1080/17482940902934791     Document Type: Conference Paper

References (41)

1. Gheorghiade M, Zannad F, Sopko G, Klein L, Pina IL, Konstam MA, et al. Acute heart failure syndromes: Current state and framework for future research. Circulation. 2005;112:3958-68. (Pubitemid 43739494)
2. Filippatos G, Zannad F. An introduction to acute heart failure syndromes: Definition and classification. Heart Fail Rev. 2007;12:87-90. (Pubitemid 46916952)
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: The task force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29:2388-442.
4. Ahmed A, Allman RM, Fonarow GC, Love TE, Zannad F, Dell'italia LJ, et al. Incident heart failure hospitalization and subsequent mortality in chronic heart failure: A propensitymatched study. J Card Fail. 2008;14:211-8. (Pubitemid 351434595)
5. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: An essential target of evaluation and treatment. Am J Med. 2006c;119(Suppl 1):S3-S10. (Pubitemid 44755377)
6. Adams KF, Jr, Fonarow GC, Emerman CL, LeJemtel TH, Costanzo MR, Abraham WT, et al. Characteristics and outcomes of patients hospitalized for heart failure in the United States: Rationale, design, and preliminary observations from the first 100,000 cases in the acute decompensated heart failure national registry (ADHERE). Am Heart J. 2005;149:209-16. (Pubitemid 40348525)
7. Cleland JG, Swedberg K, Follath F, Komajda M, Cohen- Solal A, Aguilar JC, et al. The EuroHeart Failure survey programme*a survey on the quality of care among patients with heart failure in Europe. Part 1: Patient characteristics and diagnosis. Eur Heart J. 2003;24:442-63. (Pubitemid 36286187)
8. Fonarow GC, Stough WG, Abraham WT, Albert NM, Gheorghiade M, Greenberg BH, et al. Characteristics, treatments, and outcomes of patients with preserved systolic function hospitalized for heart failure: A report from the OPTIMIZE-HF Registry. J Am Coll Cardiol. 2007;50: 768-77. (Pubitemid 47243795)
9. Fonarow GC. The acute decompensated heart failure national registry (ADHERE): Opportunities to improve care of patients hospitalized with acute decompensated heart failure. Rev Cardiovasc Med. 2003;4(Suppl 7):S21-30. (Pubitemid 37526952)
10. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296: 2217-26. (Pubitemid 44708052)
11. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Factors identified as precipitating hospital admissions for heart failure and clinical outcomes: Findings from OPTIMIZE-HF. Arch Intern Med. 2008;168:847-54. (Pubitemid 351649267)
12. Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol. 2005;96:11G-7G.
13. Beohar N, Erdogan AK, Lee DC, Sabbah HN, Kern MJ, Teerlink J, et al. Acute heart failure syndromes and coronary perfusion. J Am Coll Cardiol. 2008;52:13-6. (Pubitemid 351852938)
14. Felker GM, Leimberger JD, Califf RM, Cuffe MS, Massie BM, Adams KF, Jr, et al. Risk stratification after hospitalization for decompensated heart failure. J Card Fail. 2004;10:460-6.
15. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol. 2009;53:557-73.
16. Gheorghiade M, Gattis Stough W, Adams KF, Jr, Jaffe AS, Hasselblad V, O'Connor CM. The pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVDHF). Am J Cardiol. 2005;96:18G-25G. (Pubitemid 41338070)
17. Adamson PB, Magalski A, Braunschweig F, Bohm M, Reynolds D, Steinhaus D, et al. Ongoing right ventricular hemodynamics in heart failure: Clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol. 2003;41:565-71. (Pubitemid 36223320)
18. Chaudhry SI, Wang Y, Concato J, Gill TM, Krumholz HM. Patterns of weight change preceding hospitalization for heart failure. Circulation. 2007;116:1549-54. (Pubitemid 47511418)
19. Gheorghiade M, Gattis WA, O'Connor CM, Adams KF, Jr, Elkayam U, Barbagelata A, et al. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: A randomized controlled trial. JAMA. 2004;291:1963-71. (Pubitemid 38544277)
20. Gheorghiade M, Niazi I, Ouyang J, Czerwiec F, Kambayashi J, Zampino M, et al. Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: Results from a double-blind, randomized trial. Circulation. 2003;107: 2690-6. (Pubitemid 36667242)
21. Gheorghiade M, Zimmer C, Burnett J, Grinfeld L, Maggioni AP, Swedberg K, et al. Relationship between body weight change following hospital discharge and risk for death/ reshospitalization: An EVEREST analysis [abstract]. Eur Heart J. 2008;29:269.
22. Blair JE, Khan S, Konstam MA, Grinfeld L, Maggioni AP, Swedberg K, et al. Weight changes after hospitalisation for worsening heart failure and subsequent re-hospitalisation and mortality in the EVEREST trial. Eur Heart J. 2009;.
23. Gheorghiade M, Abraham WT, Albert NM, Gattis Stough W, Greenberg BH, O'Connor CM, et al. Relationship between admission serum sodium concentration and clinical outcomes in patients hospitalized for heart failure: An analysis from the OPTIMIZE-HF registry. Eur Heart J. 2007;28: 980-8. (Pubitemid 47343897)
24. Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, et al. Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med. 2007;167: 1998-2005. (Pubitemid 47606641)
25. Gheorghiade M, Konstam MA, Burnett JC, Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA. 2007;297:1332-43. (Pubitemid 46513234)
26. Konstam MA, Gheorghiade M, Burnett JC, Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. JAMA. 2007;297:1319-31. (Pubitemid 46513233)
27. Klein L, Massie BM, Leimberger JD, O'Connor CM, Pina IL, Adams KF, Jr, et al. Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: Results from the outcomes of a prospective trial of intravenous milrinone for exacerbations of chronic heart failure (OPTIME-CHF). Circ Heart Fail. 2008;1:1-8.
28. Filippatos G, Rossi J, Lloyd-Jones DM, Stough WG, Ouyang J, Shin DD, et al. Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: Insights from the acute and chronic therapeutic impact of a vasopressin antagonist in chronic heart failure (ACTIV in CHF) study. J Card Fail. 2007;13:360-4. (Pubitemid 46977793)
29. Blair J, Burnett JC, Konstam MA, Grinfeld L, Maggioni AP, Swedberg K, et al. Prognostic value and changes in renal function in patients admitted with acute heart failure- results from the EVEREST program [abstract]. Eur Heart J. 2008;29:270.
30. Wang NC, Maggioni AP, Konstam MA, Zannad F, Krasa HB, Burnett JC, Jr, et al. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. JAMA. 2008;299:2656-66. (Pubitemid 351831595)
31. Bart BA, Shaw LK, McCants CB, Jr, Fortin DF, Lee KL, Califf RM, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002-8. (Pubitemid 27435894)
32. Felker GM, Thompson RE, Hare JM, Hruban RH, Clemetson DE, Howard DL, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077-84. (Pubitemid 30207690)
33. Gheorghiade M, Sopko G, De Luca L, Velazquez EJ, Parker JD, Binkley PF, et al. Navigating the crossroads of coronary artery disease and heart failure. Circulation. 2006;114: 1202-13. (Pubitemid 44386485)
34. Purek L, Laule-Kilian K, Christ A, Klima T, Pfisterer ME, Perruchoud AP, et al. Coronary artery disease and outcome in acute congestive heart failure. Heart. 2006;92:598-602.
35. Flaherty JD, Bax JJ, De Luca L, Rossi JS, Davidson CJ, Filippatos G, et al. Acute heart failure syndromes in patients with coronary artery disease early assessment and treatment. J Am Coll Cardiol. 2009;53:254-63.
36. Rossi JS, Flaherty JD, Fonarow GC, Nunez E, Gattis Stough W, Abraham WT, et al. Influence of coronary artery disease and coronary revascularization status on outcomes in patients with acute heart failure syndromes: A report from OPTIMIZE- HF (organized program to initiate lifesaving treatment in hospitalized patients with heart failure). Eur J Heart Fail. 2008;10:1215-23.
37. Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARSBNP multicenter study. J Am Coll Cardiol. 2007;49:1733-9. (Pubitemid 46589928)
38. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-7. (Pubitemid 34764819)
39. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-30. (Pubitemid 30172933)
40. Abraham WT, Fonarow GC, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al. Predictors of inhospital mortality in patients hospitalized for heart failure: Insights from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). J Am Coll Cardiol. 2008;52:347-56. (Pubitemid 352005813)
41. O'Connor CM, Abraham WT, Albert NM, Clare R, Gattis StoughW, Gheorghiade M, et al. Predictors of mortality after discharge in patients hospitalized with heart failure: An analysis from the organized program to initiate lifesaving treatment in hospitalized patients with heart failure (OPTIMIZE-HF). Am Heart J. 2008;156:662-73.